The transcription factor JunD mediates transforming growth factor β-induced fibroblast activation and fibrosis in systemic sclerosis
暂无分享,去创建一个
M. Yaniv | G. Schett | O. Distler | J. Avouac | J. Distler | C. Dees | M. Tomčík | P. Zerr | A. Akhmetshina | K. Palumbo | Stefan Vollath | S. Vollath
[1] Oliver Distler,et al. Transcription Factor Fos-Related Antigen-2 Induces Progressive Peripheral Vasculopathy in Mice Closely Resembling Human Systemic Sclerosis , 2009, Circulation.
[2] B. Pasche,et al. Transforming growth factor β as a therapeutic target in systemic sclerosis , 2009, Nature Reviews Rheumatology.
[3] R. Landewé,et al. EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR) , 2009, Annals of the rheumatic diseases.
[4] S. Forbes,et al. Hepatic fibrogenesis: from within and outwith. , 2008, Toxicology.
[5] Y. Allanore,et al. Systemic sclerosis: an update in 2008. , 2008, Joint, bone, spine : revue du rhumatisme.
[6] E. Wagner,et al. Development of pulmonary fibrosis through a pathway involving the transcription factor Fra-2/AP-1 , 2008, Proceedings of the National Academy of Sciences.
[7] Oliver Distler,et al. Dual inhibition of c‐abl and PDGF receptor signaling by dasatinib and nilotinib for the treatment of dermal fibrosis , 2008, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[8] S. Hirono,et al. Treatment of arthritis with a selective inhibitor of c-Fos/activator protein-1 , 2008, Nature Biotechnology.
[9] G. Gores,et al. Cellular and molecular mechanisms of liver injury. , 2008, Gastroenterology.
[10] S. Kaufmann,et al. Starring stellate cells in liver immunology. , 2008, Current opinion in immunology.
[11] O. Distler,et al. Novel treatment approaches to fibrosis in scleroderma. , 2008, Rheumatic diseases clinics of North America.
[12] R. Gay,et al. Hypoxia-induced increase in the production of extracellular matrix proteins in systemic sclerosis. , 2007, Arthritis and rheumatism.
[13] F. Verrecchia,et al. Transforming growth factor-β and fibrosis , 2007 .
[14] G. Reynolds,et al. JunD is a profibrogenic transcription factor regulated by Jun N‐terminal kinase‐independent phosphorylation , 2006, Hepatology.
[15] E. Wagner,et al. Fos/AP‐1 proteins in bone and the immune system , 2005, Immunological reviews.
[16] H. Drexler,et al. Lack of JunD Promotes Pressure Overload–Induced Apoptosis, Hypertrophic Growth, and Angiogenesis in the Heart , 2005, Circulation.
[17] D. Pisetsky,et al. The induction of matrix metalloproteinase and cytokine expression in synovial fibroblasts stimulated with immune cell microparticles. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[18] J. Weitzman,et al. JunD protects against chronic kidney disease by regulating paracrine mitogens. , 2003, The Journal of clinical investigation.
[19] D. Edwards,et al. The Comparative Role of Activator Protein 1 and Smad Factors in the Regulation of Timp-1 and MMP-1 Gene Expression by Transforming Growth Factor-β1* , 2003, The Journal of Biological Chemistry.
[20] P. Vogt. Fortuitous convergences: the beginnings of JUN , 2002, Nature Reviews Cancer.
[21] T. Medsger,et al. Criteria for the classification of early systemic sclerosis. , 2001, The Journal of rheumatology.
[22] E. Wagner,et al. AP-1 in mouse development and tumorigenesis , 2001, Oncogene.
[23] J. Weitzman,et al. JunD protects cells from p53-dependent senescence and apoptosis. , 2000, Molecular cell.
[24] J. Iredale,et al. Control of the tissue inhibitor of metalloproteinases‐1 promoter in culture‐activated rat hepatic stellate cells: Regulation by activator protein‐1 DNA binding proteins , 1999, Hepatology.
[25] J. Ortonne,et al. Three Activator Protein-1-binding Sites Bound by the Fra-2·JunD Complex Cooperate for the Regulation of Murine Laminin α3A (lama3A) Promoter Activity by Transforming Growth Factor-β* , 1998, The Journal of Biological Chemistry.
[26] T. Medsger. Treatment of systemic sclerosis. , 1989, Rheumatic diseases clinics of North America.
[27] J. F. Woessner,et al. The determination of hydroxyproline in tissue and protein samples containing small proportions of this imino acid. , 1961, Archives of biochemistry and biophysics.
[28] S. Gay,et al. The transcription factor Fra-2 regulates the production of extracellular matrix in systemic sclerosis. , 2010, Arthritis and rheumatism.
[29] J. Varga. Systemic sclerosis: an update. , 2008, Bulletin of the NYU hospital for joint diseases.
[30] Oliver Distler,et al. Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis. , 2007, Arthritis and rheumatism.
[31] F. Verrecchia,et al. Transforming growth factor-beta and fibrosis. , 2007, World journal of gastroenterology.
[32] D. Edwards,et al. The Comparative Role of Activator Protein 1 and Smad Factors in the Regulation of Timp-1 and MMP-1 Gene Expression by Transforming Growth Factor- (cid:1) 1* , 2003 .
[33] J. Weitzman,et al. Targeted disruption of the murine junD gene results in multiple defects in male reproductive function. , 2000, Development.
[34] O. Eickelberg,et al. Transforming growth factor-beta1 induces interleukin-6 expression via activating protein-1 consisting of JunD homodimers in primary human lung fibroblasts. , 1999, The Journal of biological chemistry.